CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.900
-0.080 (-8.16%)
At close: Apr 28, 2026, 4:00 PM EDT
0.980
+0.080 (8.88%)
Pre-market: Apr 29, 2026, 6:34 AM EDT
CytoMed Therapeutics Revenue
In the year 2025, CytoMed Therapeutics had annual revenue of 860.85K SGD with 71.02% growth. CytoMed Therapeutics had revenue of 410.16K in the half year ending December 31, 2025, with 83.51% growth.
Revenue (ttm)
860.85K SGD
Revenue Growth
+71.02%
P/S Ratio
15.91
Revenue / Employee
20,020 SGD
Employees
43
Market Cap
10.65M USD
Revenue Chart
* This company reports financials in SGD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGDTC News
- 7 months ago - CytoMed Therapeutics Earnings Call Transcript: H1 2025 - Transcripts
- 7 months ago - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia - GlobeNewsWire
- 8 months ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 9 months ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 10 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 1 year ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga